Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (361-370 of 404) with videos related to

Pageof 41
Sort By:
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Clinical & Experimental Metastasis|November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 studyRenate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 studyThomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
Cancer Immunology, Immunotherapy : CII|March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 6, 2015
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Matteo Santoni, Alessandro Conti, Giuseppe Procopio, et al.
Clinical & Experimental Metastasis|February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> studyOndřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Scientific Reports|August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world studyMimma Rizzo, Andrey Soares, Enrique Grande, et al.
Pageof 41

Showing results (361-370 of 404) with videos related to

Sort By:
Pageof 41
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Clinical & Experimental Metastasis|November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 studyRenate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 studyThomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
Cancer Immunology, Immunotherapy : CII|March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 6, 2015
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Matteo Santoni, Alessandro Conti, Giuseppe Procopio, et al.
Clinical & Experimental Metastasis|February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> studyOndřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Scientific Reports|August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world studyMimma Rizzo, Andrey Soares, Enrique Grande, et al.
Pageof 41